Detalhe da pesquisa
1.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914339
2.
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.
Invest New Drugs
; 38(5): 1601-1604, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31907737
3.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(1): 88-99, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509771
4.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast Cancer Res
; 21(1): 39, 2019 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30867034
5.
Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
BMC Cancer
; 18(1): 732, 2018 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29996816
6.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1688-1700, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29146401
7.
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Breast Cancer Res
; 19(1): 54, 2017 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28464908
8.
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Oncologist
; 22(1): 12-24, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27864574
9.
Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.
Histopathology
; 70(2): 185-194, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27402148
10.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(3): 367-377, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26874901
11.
Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Breast Cancer Res Treat
; 155(3): 483-90, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26846986
12.
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Breast Cancer Res Treat
; 146(1): 153-62, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24924416
13.
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
J Clin Oncol
; : JCO2301935, 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38569132
14.
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Clin Cancer Res
; 30(9): 1984-1991, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38376912
15.
Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in Canada.
Curr Oncol
; 30(8): 7263-7274, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37623008
16.
Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
J Clin Oncol
; 41(24): 3976-3983, 2023 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37406271
17.
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
J Natl Cancer Inst
; 115(11): 1302-1309, 2023 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37184928
18.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Eur J Cancer
; 184: 48-59, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898233
19.
Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.
Oncologist
; 17(2): 172-8, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22267852
20.
Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study.
Clin Breast Cancer
; 22(1): e74-e79, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34690081